ストックスクリーナーアプリを入手
21.53
14.36%
-3.61
前日終値:
$25.14
開ける：
$21.15
24時間の取引高:
7.42M
Relative Volume:
4.59
時価総額：
$2.66B
収益：
$247.00M
当期純損益:
$-249.00M
株価収益率:
-6.9676
EPS:
-3.09
ネットキャッシュフロー:
$-267.00M
1週間 パフォーマンス:
-15.40%
1か月 パフォーマンス:
+7.65%
6か月 パフォーマンス:
+130.27%
1年 パフォーマンス:
+25.47%
1日の値動き範囲:
$20.35
$24.00
1週間の範囲:
$20.35
$26.40
52週間の値動き範囲:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
名前
Arcus Biosciences Inc
セクター
電話
(510) 694-6200
住所
3928 POINT EDEN WAY, HAYWARD, CA
RCUS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
21.53 | 3.11B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-26 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | 開始されました | H.C. Wainwright | Neutral |
| 2024-10-08 | 開始されました | Wells Fargo | Overweight |
| 2022-11-18 | 開始されました | BofA Securities | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2020-11-24 | 開始されました | Berenberg | Buy |
| 2020-11-23 | 開始されました | Evercore ISI | Outperform |
| 2020-04-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-09-27 | 開始されました | Mizuho | Buy |
| 2019-05-24 | 再開されました | Citigroup | Buy |
| 2018-10-09 | 開始されました | Wedbush | Outperform |
| 2018-04-09 | 開始されました | Citigroup | Buy |
| 2018-04-09 | 開始されました | Goldman | Neutral |
| 2018-04-09 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Arcus Biosciences Inc (RCUS) 最新ニュース
Arcus Calls Quits On Anti-TIGIT Candidate After Phase III Termination - Citeline News & Insights
Arcus shifts effort, bears down on would-be ‘anchor’ in RCC - BioWorld MedTech
Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug - Benzinga
H.C. Wainwright raises Arcus Biosciences stock price target to $32 on lower expenses - Investing.com Canada
Why Arcus Biosciences just reversed its 287% eight-month winning streak - MSN
Why Did Arcus Biosciences Stock Slump 10% Today? - Asianet Newsable
Truist Securities lowers Arcus Biosciences stock price target on trial failure - Investing.com
RCUS: HC Wainwright & Co. Raises Price Target for Arcus Bioscien - GuruFocus
Truist Securities Adjusts Arcus Biosciences Price Target to $30 From $39, Maintains Buy Rating - marketscreener.com
Arcus Biosciences (RCUS) Shares Decline Over 11% in Recent Tradi - GuruFocus
Arcus scraps late-stage cancer trial after weak survival data - Reuters
Arcus Biosciences (RCUS) Drops After Halting Phase 3 Cancer Tria - GuruFocus
Arcus Biosciences Stock (RCUS) Collapses 17% after Failed Stomach Cancer Study - TipRanks
GILD: Gilead and Arcus End STAR-221 Study Due to Lack of Efficac - GuruFocus
Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update - marketscreener.com
Arcus Biosciences Discontinuing Gastric, Esophogeal Cancer Candidate Trial; Shares Fall - marketscreener.com
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug - Seeking Alpha
Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment - marketscreener.com
Arcus Biosciences stock falls after discontinuing phase 3 cancer study By Investing.com - Investing.com Australia
Arcus Biosciences Discontinues Phase 3 STAR-221 Study - TradingView
Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio - TradingView
Gilead, Arcus scrap late-stage trial of cancer drug combo - Yahoo
Arcus Biosciences (NYSE: RCUS) ends STAR-221, backs casdatifan and I&I pipeline into 2028 - Stock Titan
Arcus cancels work on Gilead-partnered cancer combo after trial setback - Yahoo Finance
Decliners Report: Why Arcus Biosciences Inc stock attracts global investors2025 Volatility Report & Weekly Watchlist for Consistent Profits - moha.gov.vn
Avoiding Lag: Real-Time Signals in (RCUS) Movement - news.stocktradersdaily.com
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Arcus Biosciences (NYSE: RCUS) sets $25.80 inducement grant under 2020 plan - Stock Titan
Arcus Biosciences (NYSE:RCUS) Reaches New 1-Year HighWhat's Next? - MarketBeat
Is Arcus Biosciences Stock Built to Withstand a Pullback? - Trefis
Fisher Asset Management LLC Decreases Stock Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
Insider Selling: Arcus Biosciences (NYSE:RCUS) President Sells 82,997 Shares of Stock - MarketBeat
Arcus Biosciences, Inc. $RCUS Shares Acquired by Tema Etfs LLC - MarketBeat
Arcus Biosciences (NYSE:RCUS) Downgraded by Wall Street Zen to Sell - MarketBeat
Is Arcus Biosciences Inc. stock cheap by valuation metricsWeekly Market Outlook & Low Risk High Win Rate Stock Picks - Newser
Can Arcus Biosciences Inc. stock ride next bull market cycleShort Setup & Real-Time Market Trend Scan - Newser
Decheng Capital LLC Has $1.30 Million Holdings in Arcus Biosciences, Inc. $RCUS - MarketBeat
How Arcus Biosciences Inc. stock performs during market turbulenceJuly 2025 Review & Weekly High Potential Alerts - Newser
What is the fair value estimate for Arcus Biosciences Inc. stock in 2025Earnings Overview Report & Safe Entry Momentum Stock Tips - Newser
How Arcus Biosciences Inc. stock behaves in tightening cyclesJuly 2025 Levels & Weekly High Conviction Ideas - Newser
RCUS: Casdatifan shows superior efficacy in RCC, with pivotal trials and strong financial backing - TradingView
Arcus Biosciences (NYSE:RCUS) Hits New 52-Week HighStill a Buy? - MarketBeat
Arcus Biosciences, Inc. $RCUS Shares Purchased by Geode Capital Management LLC - MarketBeat
How Arcus Biosciences Inc. stock compares with market leadersJuly 2025 Analyst Calls & Safe Entry Point Alerts - Newser
Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 1,900 Shares - MarketBeat
Arcus Biosciences stock hits 52-week high at 26.32 USD By Investing.com - Investing.com India
Arcus Biosciences stock hits 52-week high at 26.32 USD - Investing.com
SG Americas Securities LLC Buys 17,111 Shares of Arcus Biosciences, Inc. $RCUS - MarketBeat
How dovish Fed policy supports Arcus Biosciences Inc. stock2025 Pullback Review & Daily Stock Trend Reports - Newser
Pancreatic Cancer Pipeline Drugs Insights Report 2025 | - openPR.com
Arcus Biosciences Executive Sells Shares - TradingView
Arcus Biosciences Inc (RCUS) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):